These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28247446)

  • 1. The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma.
    Liang R; Lin Y; Yuan CL; Liu ZH; Li YQ; Luo XL; Ye JZ; Ye HH
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28247446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-650 Promotes the Metastasis and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression.
    Han LL; Yin XR; Zhang SQ
    Cell Physiol Biochem; 2018; 51(3):1179-1192. PubMed ID: 30481780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.
    Han LL; Yin XR; Zhang SQ
    Int J Oncol; 2018 Dec; 53(6):2433-2444. PubMed ID: 30272278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
    Li Y; Zhuang W; Huang M; Li X
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1051-1057. PubMed ID: 31097223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway.
    Bao L; Yuan L; Li P; Bu Q; Guo A; Zhang H; Cui N; Liu B
    Cell Physiol Biochem; 2018; 50(2):437-451. PubMed ID: 30308519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
    Guo C; Wang X; Liang L
    Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
    Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
    Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression.
    Wu A; Li J; Wu K; Mo Y; Luo Y; Ye H; Mai Z; Guo K; Wang Y; Li S; Chen H; Luo W; Yang Z
    Biomed Pharmacother; 2016 Aug; 82():290-7. PubMed ID: 27470365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
    Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
    J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
    Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer.
    Zhao C; Chen J; Liu Y; Ju S; Wang G; Wang X
    Bioengineered; 2021 Dec; 12(2):11648-11661. PubMed ID: 34699318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
    Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
    Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.
    Yin G; Liu Z; Wang Y; Dou C; Li C; Yang W; Yao Y; Liu Q; Tu K
    BMC Cancer; 2016 Feb; 16():103. PubMed ID: 26879601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
    Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
    J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma.
    Pan K; Liang XT; Zhang HK; Zhao JJ; Wang DD; Li JJ; Lian Q; Chang AE; Li Q; Xia JC
    Mol Med; 2012 May; 18(1):507-18. PubMed ID: 22281836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.
    Chen CL; Wang Y; Pan QZ; Tang Y; Wang QJ; Pan K; Huang LX; He J; Zhao JJ; Jiang SS; Zhang XF; Zhang HX; Zhou ZQ; Weng de S; Xia JC
    Oncotarget; 2016 Mar; 7(13):16248-61. PubMed ID: 26919247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.